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Summary Assessment of response of skeletal metastases to systemic therapy is currently dependent on
radiological evidence of bone healing. We have performed a prospective study of additional response criteria
in patients with progressive bone metastases from breast cancer. Changes in these potential markers of
response were correlated with the radiological response and the time to treatment failure (TTF).
Successful systemic therapy typically led to a transient increase in osteoblast activity ('flare'), a reduction in
osteoclast activity and symptomatic improvement. After 1 month a > 10% rise in serum osteocalcin (BGP)
and alkaline phosphatase bone isoenzyme (ALP-BI) and a > 10% fall in urinary calcium excretion were seen
in 14/16 patients with radiographic evidence of bone healing (UICC partial responders). In comparison
similar biochemical changes at 1 month were seen in only 4/20 patients with progressive disease (P<0.001).
The predictive value and diagnostic efficiency (DE) of changes at 1 month in biochemical measurements
and symptom score has been calculated. The combination of a > 10% rise in ALPBI and BGP and a > 10%
fall in urinary calcium excretion had a DE of 89% for discriminating response from progression, 88% for
response from non-response (progressing+ no change patients), and 76% for TTF of >6 months from TTF of
<6 months. Serum calcium, tartarte resistant acid phosphatase (TRP), urinary hydroxyproline excretion and
bone scan changes were unhelpful in discriminating between patient groups.
Independent confirmation is needed, but our results suggest there are reliable alternatives to plain
radiography in the early assessment of response of bone metastases to treatment.
Bone metastases are common in breast cancer, affecting 69%
of patients with advanced disease (Coleman & Rubens,
1987). The clinical course is often long and patients require
palliative treatment - local radiotherapy and specific sys-
temic therapy - for many months or years. Remissions are
frequent, but the effect of treatment is difficult to measure
objectively (Coleman & Rubens, 1985). The adoption of the
UICC criteria of response (Hayward et al., 1977) have
improved the reporting of clinical trials in breast cancer, but
assessing response in bone remains imprecise.
The UICC criteria of response require radiological evi-
dence (recalcification) in lytic disease. This may not be
visible for 6 months or more, resulting in underestimation of
the true response rate to treatment. New methods of assess-
ing response are needed to improve patient management and
evaluation of specific treatments. Radionuclide bone scan-
ning (Rossleigh et al., 1984), biochemical parameters of bone
metabolism (Hortabagyi et al., 1984), tumour markers such
as carcino-embryonic antigen (Palazzo et al., 1986) and
measurement of symptomatic response (Coombes et al.,
1983) have all been proposed as useful alternatives or
adjuncts to assessment of plain radiographs.
We report here a prospective study of patients receiving
systemic therapy for bone metastases from breast cancer in
which we have evaluated alternative assessment criteria.
Correlation with the UICC response was made and para-
meters which predicted radiological response identified.
Patients and methods
Seventy women with advanced breast cancer and progressing
bone metastases, median age 58 (range 32-82 years) were
studied. All patients had radiographically confirmed bone
metastases. In 29 (41%) patients metastatic spread was
confined to the skeleton. Metastatic spread in the other 41
patients was to all common sites including liver and lung.
No attempt was made to select patients on a particular
treatment. Thirty-five received an endocrine treatment and
35 chemotherapy. The alternative response criteria studied
included biochemical markers of bone cell (osteoblast and
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osteoclast) activity, radionuclide bone scans and symptoma-
tic assessment.
Osteoblast activity was monitored by serial measurements
of alkaline phosphatase bone isoenzyme (ALP-BI) and osteo-
calcin (BGP). Serum calcium, tartrate resistant acid phos-
phatase (TRP) and urinary excretion of calcium and
hydroxyproline were measured to assess osteoclast activity.
Serum for measurement of BGP, ALP-BI and TRP was
obtained from a morning blood sample following centri-
fugation. The aliquot for TRP was acidified with 20p1 of
5 M acetate buffer (pH 5) per ml of serum. All samples were
frozen within 6h and stored at -20°C. A morning spot
urine sample was collected for measurement of calcium and
hydroxyproline excretion after an overnight fast and stored
at -20°C. Foods rich in collagen were avoided for 18h prior
to urine collection for hydroxyproline. Following pre-
treatment estimations measurements of serum calcium, BGP,
and urinary calcium excretion were performed monthly,
ALP-BI at 1, 3 and 6 months during treatment and TRP
and urinary hydroxyproline excretion 3 monthly.
Bone scans, with plain radiographs of abnormal areas,
were performed before treatment and repeated three
monthly. Standard overlapping views were taken 3-4h after
injection of 500 megabecquerels of technetium99m labelled
methylene diphosphonate (MDP). Symptomatic response
was assessed by a questionnaire completed by the patient.
Severity of pain and mobility were rated by the patient and
combined with a scoring of analgesic consumption and the
UICC performance status to produce an overall symptom
score which was expressed as a percentage of the maximum
possible score. (Details of pain and activity questionnaire
available from the authors on request).
ALP-BI was measured by the modified heat-inactivation
technique described by Moss & Whitby (1975). This method
utilises the different heat stability characteristics of the bone
and liver isoenzymes. The total enzyme activity is measured
and the presence of significant amounts of ALP from other
sources (e.g. gut) excluded by electrophoresis. Serum is
incubated at 56°C and at this temperature more than 99% of
the bone isoenzyme decays within 15min. The residual
activity of the sample is measured after 15 and 25min
incubation and reflects the inactivation rate of the liver
component. The total liver component can be determined by
extrapolation from these two measurement and ALP-BI
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calculated by subtraction of the liver component from the
total baseline activity.
BGP was measured by radioimmunoassay (Immuno
Nuclear RIA). The assay which has been described previ-
ously (Price et al., 1980) uses antiserum to bovine BGP
raised in rabbits and bovine BGP as a standard and tracer.
Antibody-bound and free 1251 labelled bovine BGP are
separated by the double antibody technique. All samples
were measured in duplicate.
TRP was determined at 37°C with 4-nitrophenylphosphate
(10 mol/l) as substrate in citrate buffer (O.1 mmolI1 , pH 5)
in the presence of L(+) tartaric acid (O.1moll-1). After
15min the reaction was stopped with 0.5 vol of sodium
hydroxide (0.5moll-1) and the reaction product determined
by reading absorbance at 405nm. The reference range for
this method is 3-1liul-1 (Efstradiatis & Moss, 1985).
Serum and urinary concentrations of calcium and creati-
nine were measured on a standard autoanalyser. Urinary
calcium excretion was expressed as a molar ratio of calcium
to creatinine. Hydroxyproline was measured using the
method described by Grant et al. (1984) and also expressed
as a molar ratio to creatinine.
The UICC criteria of response were used to define res-
ponse to treatment (Hayward et al., 1977). Radiological
evidence of healing was necessary for a patient to be
determined a 'responder'. In this study, the no change
response category denoted stabilisation of disease for a
minimum of 12 weeks. Assessment of response in bone was
possible in 53 patients. In the other 17 patients the response
in bone could not be determined. This was because of early
death or extra-skeletal progression in 12 patients, treatment
toxicity in two, radiotherapy to all evaluable sites of disease
in a further two and the loss of one patient to follow-up.
Statistical analysis included the chi-square test with Yates
correction for comparing the difference between groups and
the Mann-Whitney test for ranked data. The predictive
value (PV) of a test discriminating between response groups
is expressed as (1) the number of patients with a positive test
showing radiological evidence of healing (or in some cases
TTF>6 months), divided by the total number of patients
with a positive test (PV+); (2) the number with a negative
test not showing radiological evidence of healing (or in some
cases TTF<6 months), divided by the total number of
patients with a negative test (PV-) (Ransohoff & Feinstein,
1978) and (3) the number with the correct diagnosis (true
positive plus true negative), divided by the total number of
evaluable patients to calculate the diagnostic efficiency (DE)
(Galen & Gambino, 1975).
For the purposes of calculating PV+, PV- and DE of
tests patients were grouped according to the UICC response
category (response (PR) versus progression (PD) and PR
versus non-responders (PD plus no change (NC)). In addi-
tion patients were grouped according to whether their skele-
tal disease progressed within 6 months of entry onto the
study (Time to Treatment Failure TTF<6 months n=31),
or after this time (TTF>6 months, n=22). A 10% rise was
taken as the cut-off for ALP-BI and BGP, and a 10% fall
for calcium excretion and symptom score.
Results
Sixteen of 53 (30%) patients achieved a UICC partial
response (PR) in bone, 14 showed no change (NC) and 23
had progressive disease (PD). No patient had a complete
response. The median duration of response was 12 months
(range 5-33+ months). Successful systemic therapy typically
led to a transient increase in osteoblast activity, a reduction
in osteoclast activity, paradoxical deterioration in the bone
scan appearances and symptomatic improvement. The serial
measurements of biochemical parameters and the symp-
tom score are shown in Table I.
Osteoblast activity
Baseline raised levels of ALP-BI (>120iul-1) and
BGP(>3.8ngml-1) were found in 51/62 (82%) and 29/64
(45%) of patients. A rise in ALP-BI, maximal at one month
and BGP, maximal at two months, is seen in responding
patients followed by a gradual fall over subsequent months
as healing continues (Figures 1 & 2). All responders showed
a rise in ALP-BI and 15/16 (94%) a rise in BGP.
The mean rise at 1 month in ALP-BI in the responders
was 224iu -1, (median 172iu 1 1, 76% increase from base-
line), significantly greater than the change in the progressing
groups of patients. Patients in the no change response
category had a small rise in ALP-BI (mean 23iul-1), not
significantly different from the responding or progressing
groups of patients.
The mean rise in BGP was 2.2 ngml-1 (median
2.3ngml-1, 81% increase from baseline), again significantly
greater than progressing patients (P<0.01). Patients in the
no change response category had a small rise in BGP (mean
1.9ngml-1), not significantly different from the other two
response groups.
After one month 15/16 (94%) responding patients showed
a > 10% rise in both ALP-BI and BGP compared with 7/22
(31%) with progressive disease (P<0.001). 16/22 (73%)
patients with radiologically responding, or static disease for
more than 6 months (TTF>6 months), had >10% increases
in ALP-BI and BGP compared with 8/30 (27%) progressing
within 6 months (TTF<6 months) (P<0.005).
Table I Serial biochemical and symptom score measurements in relation to UICC response group. Values are means (SEM)
Response Months
Parameter Group
ALP-BI
(iul- 1)
BG (ngml-')
Calcium excretion
(mmolmol -
creatinine)
Symptom score
Serum calciumc
(mmoll-)
PR
NC
PD
PR
NC
PD
PR
NC
PD
PR
NC
PD
PR
NC
PD
307
352
425
0
(42)
(94)
(80)
5.2 (0.8)
5.1 (0.9)
4.1 (0.6)
0.75 (0.15)
0.80 (0.15)
0.74 (0.06)
7.3 (1.2)
7.3 (1.2)
9.8 (0.6)
2.24 (0.04)
2.29 (0.10)
2.40 (0.03)
2 1
531 (94)'
375 (93)
524 (95)
7.4
7.0
4.2
(1.0)a
(I.I)b
(0.6)
0.41 (0.10)a
0.45 (0.11)b
0.69 (0.10)
5.9 (1.0)
5.9 (1-3)
9.8 (0.7)
2.23 (0.02)
2.24 (0.03)
2.40 (0.06)
3 4
339 (69)
- 258 (71)
448 (134)
7.9 (0.9)
6.4 (1.3)
4.7 (1.0)
0.36 (0.08)
0.64 (0.18)
0.80 (0.17)
4.3 (0.8)
5.9 (1.4)
9.0 (1.2)
2.24 (0.02)
2.23 (0.04)
2.44 (0.07)
7.2 (1.0)
4.9 (0.8)
6.5 (1.9)
0.42 (0.10)
0.54 (0.12)
1.15 (0.42)
3.4 (0.9)
6.4 (1.4)
9.3 (4.4)
2.19 (0.02)
2.31 (0.04)
2.53 (0.13)
6.5 (1.1)
5.6 (1.2)
5 6
233 (28)
472 (216)
6.3 (1.2) 5.8 (0.9)
4.4 (0.7) 4.5 (1.0)
0.45 (0.10) 0.47 (0.10) 0.58 (0.16)
0.64 (0.16) 0.52 (0.20) 0.42 (0.18)
3.0 (0.7) 2.6 (0.7) 2.4 (0.6)
2.0 (0.7) 2.5 (1.0) 2.0 (1.0)
2.21 (0.03) 2.27 (0.04) 2.24 (0.03)
2.36 (0.08) 2.20 (0.05) 2.13 (0.05)
PR =partial response, NC =no change, PD =progressive disease; Significance of change from baseline after 1 month of treatment; ap<0.01,
bp<0.05; cSerum calcium corrected for albumin concentration.BIOCHEMICAL PREDICTION OF RESPONSE OF BONE METASTASES
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Figure 1 Mean percentage change from baseline in alkaline
phosphatase bone isoenzyme for the three UICC response
groups. Closed circles are partial responders, triangles no change
patients and open circles progressive disease. Error bars are s.e.m.
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Figure 2 Mean percentage change from baseline in osteocalcin
(BGP) for the three UICC response groups. Response group
symbols as in Figure 1. Error bars are s.e.m.
Osteoclast activity
Baseline values of urinary calcium excretion were raised in
40/61 (66%) of patients (>0.5mmol calciummol'1 creati-
nine). Figure 3 shows the changes in urinary calcium excre-
tion for the three response groups. A fall in calcium
Months
Figure 3 Mean percentage change from baseline in urinary
calcium excretion for the three UICC response groups. Response
group symbols as in Figure 1. Error bars are s.e.m.
excretion, nadir at 2 months, was seen in responding patients.
The mean fall in urinary calcium excretion at one month was
0.34mmol-mol-1 creatinine (median 0.29mmolmol -3 creati-
nine, 49% reduction from baseline), significantly greater
than the change in progressing patients. Calcium excretion
fell also in patients in the no change response group (mean
0.35 mmol-mol-1 creatinine) although this reduction was not
significantly different from progressing patients.
At 1 month 15/16 (94%) responders had a >10% reduc-
tion in calcium excretion compared with 10/21 (48%) with
progressive disease (P<0.02). 17/22 (77%) patients with
TTF>6 months had a >10% reduction in calcium excretion
compared with 14/29 (48%) with TTF<6 months
(P>0.05NS).
Serum calcium did not change significantly in any of the
response groups. Hypercalcaemia developed in 6 patients
and invariably indicated progressive disease.
Serial urinary hydroxyproline excretion measurements
were made in 47 patients. Raised levels (>32mmolmol-'
creatinine) before treatment were found in 39 (83%). Despite
a reduction in calcium excretion and evidence of bone
healing, these levels remained high in many responding
patients and changes in hydroxyproline excretion did not
correlate with response.
Raised baseline levels of acid phosphatase (TRP
> 1Iiu 1 ') were found in 7/65 (11%) patients. Serial meas-
urements were performed in 35 patients; 9 responders, 9 with
stable disease and 17 with progression. An increase in TRP
after 3 months was seen in 13/17 with progressive disease
compared with 2/9 responders (P<0.05).
Symptomatic response
Figure 4 shows the symptomatic response to treatment. After
1 month 8/16 (50%) responders reported symptomatic bene-
fit with a reduction in symptom score of > 10% compared
with 4/23 (17%) with progressive disease (P>0.05NS).
Similarly, the number showing symptomatic benefit at I
month was not significantly different in those with TTF>6
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Figure 4 Mean percentage change from baseline in symptom
score for the three UICC response groups. Response group
symbols as in Figure 1. Error bars are s.e.m.
months compared with TTF <6 months. By 3 months
symptomatic improvement had occurred in all responding
patients. Symptomatic deterioration indicated progression of
disease except in one responder with a temporary restriction
of mobility and post-operative pain following prophylactic
pinning of a femur two weeks after starting systemic
treatment.
Radionuclide bone scans
All patients had foci of abnormal tracer uptake on the
baseline bone scan which were typical of metastatic involve-
ment of the skeleton. In 12/16 (75%) responders, a paradoxi-
cal deterioration in the bone scan appearances at 3 months
was seen characterised by increased activity in baseline
lesions and the appearance of new foci of increased tracer
uptake; changes which were indistinguishable from progress-
ive disease. In 3 responders the bone scan was unchanged at
3 months and a reduction in lesion activity was seen in only
one patient. New bone scan lesions on the three month scan
were seen in 12/16 (75%) responders, 2/14 (14%) with stable
disease and 9/14 (64%) with progressive disease. Bone scans
performed in responding patients at 6 months showed
improvement from the appearances at 3 months and new
lesions appearing after this time were indicative of new bone
lesions.
Predictive value of tests
Table II shows the predictive values (PV+ and PV-) and
diagnostic efficiency (DE) of 1 month changes in ALP-BI,
BGP, urinary calcium excretion and symptom score. A cut-
Table II The predictive values (PV+ and PV-) and diagnostic efficiency (DE) of biochemical
and symptomatic changes after 1 month of treatment in discriminating between response
groupsa. Expressed as fractions and (%)
Change in response
criteria
> 10% t in ALPBI
>10% t in BGP
> 10% in urinary
calcium excretion
>10% in symptom
score
>10% T in ALPBI +
>10% T in BGP
>10% T in ALPBI+
> 10% in urinary
calcium excretion
>10% t in BGP+
> 10% in urinary
calcium excretion
>10% T in ALPBI +
>10% T in BGP+
>10% in urinary
calcium excretion
>10% T in ALPBI +
>10% T in BGP+
>10% in urinary+
calcium excretion +
> 10% in symptom
score
Response
discrimination
PR v.s. PD
PR v.s. NR
TTF>6 v.s. TTF<6
PR v.s. PD
PR v.s. NR
TTF>6 v.s. TTF<6
PR v.s. PD
PR v.s. NR
TTF>6 v.s. TTF<6
PR v.s. PD
PR v.s. NR
TTF>6v.s. TTF<6
PR v.s. PD
PR v.s. NR
TTF>6v.s. TTF<6
PR v.s. PD
PR v.s. NR
TTF>6 v.s. TTF<6
PR v.s. PD
PR v.s. NR
TTF>6 v.s. TTF<6
PR v.s. PD
PR v.s. NR
TTF>6 v.s. TTF<6
PR v.s. PD
PR v.s. NR
TTF>6 v.s. TTF<6
Pv-
10/10 (100)
19/19 (100)
16/19 (84)
12/13 (92)
18/19 (95)
14/19 (74)
11/12 (92)
18/19 (95)
15/19 (79)
14/19 (74)
19/25 (76)
18/25 (72)
PV+
16/29 (55)
16/34 (47)
19/34 (56)
15/26 (58)
15/34 (44)
17/34 (50)
15/25 (60)
15/32 (47)
18/32 (56)
11/20 (55)
11/28 (55)
14/28 (50)
15/22 (68)
15/24 (63)
16/24 (67)
15/23 (65)
15/25 (60)
16/25 (64)
14/18 (78)
14/23 (61)
15/23 (65)
14/18 (78)
14/18 (78)
14/18 (78)
9/11 (82)
9/11 (82)
9/11 (82)
DE
26/38 (68)
35/52 (67)
35/52 (67)
27/39 (69)
32/53 (60)
31/53 (57)
26/37 (70)
33/51 (64)
33/51 (64)
25/39 (64)
30/52 (58)
32/52 (62)
31/38 (82)
43/52 (83)
39/52 (75)
27/36 (75)
39/50 (78)
35/50 (70)
31/37 (84)
41/52 (79)
37/52 (71)
32/36 (89)
44/50 (88)
38/50 (76)
27/36 (75)
41/50 (82)
35/50 (70)
16/17
28/29
23/29
12/13
24/25
19/15
17/19
27/29
22/29
17/19
30/32
24/32
18/25
32/39
26/39
(94)
(97)
(79)
(92)
(96)
(76)
(89)
(93)
(76)
(89)
(94)
(75)
(72)
(82)
(67)
PR=partial response, PD =progressive disease, NR =no response (no change+progressive
disease); TTF>6=time to progression>6 months, TTF<6 =time to progression <6 months;
aSee methods for definition of predictive values and diagnostic efficiency.BIOCHEMICAL PREDICTION OF RESPONSE OF BONE METASTASES 209
off of a 10% change from baseline (increase for ALP-BI and
BGP, decrease for urinary calcium excretion and symptom
score) was selected. From Table II it is clear that the PV-
of single biochemical parameters is high but the PV+ and
DE are relatively low. Combining parameters improved the
discrimination and a combination of a > 10% rise in ALP-
BI and BGP wth a > 10% fall in calcium excretion produced
the highest DE. The DE with this combination was 89% for
discriminating between response (PR) and progression (PD),
88% between PR and no response (PD plus no change NC)
and 76% between TTF of >6 months and TTF of <6
months. The addition of symptom score did not improve the
DE further.
Figure 5a and 5b show the discriminant effect of ALP-BI,
BGP and urinary calcium excretion in Venn diagrams. The
same cut-offs have been used. The intersection of the three
sets in (5a) contains 14/16 responding patients but only 3/23
with progressive disease (P<0.001). In 5b all 53 patients are
represented and divided into two groups according to time
to progression. (TTF>6 months at the top and <6 months
below). The intersection of the three sets contains only 4/31
patients progressing within 6 months compared with 14/22
patients relapsing after this time (P<0.001).
Discussion
Metastatic bone destruction results from malignant cells in
the bone marrow cavity secreting paracrine factors which
stimulate osteoclasts to resorb bone (Mundy, 1987). In lytic
metastases, the normal coupling between osteoblast and
osteoclast function is disturbed and bone resorption predo-
minates. Control of the tumour by systemic therapy reduces
osteoclast activity and allows bone healing, mediated by
osteoblasts, to occur. This study has shown that biochemical
monitoring of bone cell function can predict eventual radio-
logical response.
Response to therapy resulted in a flare in osteoblast
activity and reduction in the rate of bone resorption, changes
which were significantly different from those seen with
progressive disease. A transient rise in ALP-BI and BGP,
reaching a peak at 1-2 months occurred. As the response
continued both parameters fell; the fall in BGP occurring
more slowly reflecting continued remineralization. A tran-
sient rise in alkaline phosphatase during the first month of
treatment has been noted before (Hortabagyi et al., 1984)
but this was not seen in all responders, possibly because
isoenzyme measurements were not performed. In another
study (Coombes et al., 1983) changes in ALP were unhelpful
but repeat measurements were not made until 2-4 months, a
time when osteoblast activity is falling again.
The flare in osteoblast activity is seen also on serial bone
scans performed during the first 6 months of treatment
(Rossleigh et al., 1984, Coleman et al., 1986). This results in
a paradoxical deterioration of the bone scan appearances in
responding patients characterised by increased activity in
baseline lesions and the appearance of new foci of increased
tracer uptake. These findings are discussed in more detail
elsewhere (Coleman et al., 1988).
Control of metastatic disease led to a reduction in urinary
calcium excretion as the rate of bone resorption slowed. The
use of the calcium excretion index (Peacock et al., 1969) has
been reported previously as a marker of response (Campbell
et al., 1983) and we confirm their results. No patient with
a b
Figure 5 Biochemical discrimination of response shown in Venn diagrams. Set A are patients showing a > 10% rise in ALP-BI,
Set B a > 10% rise in BGP and Set C a > 10% fall in urinary calcium excretion (all after 1 month of treatment). In (a) partial
responders (n = 16) are compared with progressive disease (n = 23) and in (b) TTF>6 months (n = 22) compared with TTF <6
months (n = 31). (A =rise in ALP-BI, B =rise in osteocalcin, C = fall in calcium excretion).
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responding disease or static disease for more than 6 months
had a rise in calcium excretion at 1 month. Changes in the
serum calcium within the normal range were unable to
predict response but the development of hypercalcaemia
during therapy invariably indicated progressive disease.
Increased bone resorption leads to an increase in hydroxy-
proline excretion but in this study serial measurements
correlated poorly with response; a rise was seen in 73% of
non-responders but levels fell in only 50% of responders.
Similar results have been noticed previously (Coombes et al.,
1983) and attributed to either methodological problems with
the assay or contribution from dietary and extra-skeletal
sources.
Acid phosphatase is produced by several cell types but
isoenzyme measurements enable indirect assessment of
osteoclast activity. The tartrate-resistant phosphatase (TRP)
isoenzyme is mainly derived from osteoclasts (Efstrdiatis &
Moss, 1985) and metastatic bone disease causes levels to rise
(Yarrison et al., 1976). Although levels did not often fall as a
result of effective therapy a rise was more common in
progressive disease (P<0.02). Further study of this marker
of bone metabolism in monitoring therapy may be
worthwhile.
The relief of symptoms is the principal aim of palliative
therapy and objective response correlated well with sympto-
matic response. Measurement of symptoms is both difficult
and poorly standardised. The pain questionnaire used here
was completed by the patient and provided a semi-
quantitative assessment of pain, mobility and analgesic use.
From these data a symptom score was easily computed.
Patients responding to therapy showed a steady improve-
ment in symptoms while patients progressing had at best
only a slight and transient relief of symptoms, usually
attributable to local radiotherapy. Worsening of symptoms
indicated progressive disease.
The ability of a specified change (> 10%) from baseline in
the values of ALP-BI, BGP and urinary calcium excretion to
predict response after 1 month of treatment was determined
by calculating the predictive values (PV+ and PV-) and
diagnostic efficiency (DE). The PV- of a single test was
high, but the more clinically useful PV+ and thus the DE
were relatively low. However, the combination of > 10% rise
in ALP-BI and BGP and >10% fall in urinary calcium
excretion increased PV+, with little effect on PV- and
hence, increased the DE. The DE of this combination was
89% for discriminating response (PR) from progression
(PD). The use of this predictive model was extended to
patients with radiologically stable disease by adding this
group to those with PD as non-responders (DE 88%) or
divided, according to the time to treatment failure (TTF),
between responding and progressing patients (DE 76%).
In conclusion, biochemical monitoring appears to be a
good alternative to plain radiography early on in treatment
as it provides an indication of response long before radio-
logical changes can be expected. We suggest using a >10%
rise in ALP-BI and BGP with a 10% fall in calcium
excretion after 1 month of treatment as an index for
predicting response. However, our conclusions are based on
a retrospective analysis of the data and it is recognised that
independent prospective confirmation of our results is
necessary.
We wish to thank Ms. Sue Hoare for hydroxyproline measurements,
Mr George Chik for routine urine biochemistry and the nursing staff
of the Hedley Atkins Unit for their help with sample collection.
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